Study guide

1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

Key Takeaways Explain This Topic AI

Domain 1C conditions are managed with a repeatable framework: phenotype recognition → right test tier → cascade relatives → surveillance matched to organ risk → treatment lever (diet, ERT, surgery thresholds, devices)

Screening (NBS, carrier screening, cascade ECG/echo) differs from diagnostic testing; counselors must not conflate a screen-positive result with a confirmed diagnosis

Surveillance interval and modality follow the catastrophic risk—aorta imaging for Marfan/LDS, ammonia sick-day plans for urea-cycle, CK/cardiac follow-up for DMD carriers, QTc/drug review for LQTS

Treatment themes cluster: dietary/medical for IEMs, ERT/SRT for selected LSDs, gene/sequence-modifier therapies for SMA, and surgical/device therapy for aortopathy/arrhythmia syndromes

Diagnostic strategy chooses karyotype/CMA/single-gene/panel/exome based on suspected mechanism, urgency, and whether a familial variant already exists for targeted testing

Last updated: August 2026

1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

Quick Answer: For any Domain 1C condition, run the same loop: (1) name the catastrophe to prevent, (2) choose screening vs diagnostic testing correctly, (3) cascade at-risk relatives, (4) assign organ-specific surveillance, (5) activate the disease’s treatment lever. The exam rewards next-step judgment more than trivia.

Sections 1.17–1.19 taught the diseases. This section teaches the operating system genetic counselors use across them—exactly how ABGC Domain 1 knowledge items on natural history, surveillance, treatment, and testing strategy hang together.

The Five-Step Domain 1C Loop

Step Question you answer aloud Example

1. Catastrophe What kills or disables if missed? Aortic dissection; hyperammonemic coma; FXS expansion; SMA respiratory failure

2. Test role Is this screen, diagnostic, predictive, or carrier testing? NBS MCADD screen vs ACADM confirmation; FBN1 diagnostic vs cascade predictive

3. Cascade Who else shares risk now? DMD maternal relatives; AD Marfan children/siblings; AR SMA partner testing

4. Surveillance Which organ, how often, what modality? Echo for Marfan; ECG for LQTS; CK/cardio for DMD carriers; ovarian evaluation for FXPOI

5. Lever Diet, ERT, drug, device, surgery, gene therapy, supports? Phe diet; Pompe ERT; SMA disease-modifying therapy; β-blocker/ICD; aortic surgery thresholds

If a vignette asks for the “most appropriate next step,” map it onto this loop before picking an answer.

Screening vs Surveillance vs Diagnostic Testing

These words are not interchangeable on the CGC exam.

Term Definition for counseling Domain 1C examples

Screening Test offered to an asymptomatic or broad population to identify higher risk Newborn screening for PKU/MCADD/galactosemia/SMA (jurisdiction-dependent); ethnicity-informed or universal carrier screening; cascade ECG in LQTS relatives

Surveillance Scheduled monitoring after risk is known Annual (or more frequent) aortic imaging in Marfan/LDS; timed developmental/cardiac follow-up in DMD; neurologic follow-up in premutation FXTAS risk

Diagnostic testing Test to confirm/refute disease in a symptomatic person or fetus GAA sequencing in hypotonic infant with cardiomyopathy; COL3A1 testing after arterial rupture; CMA/exome for syndromic DD

Predictive / presymptomatic Testing an asymptomatic relative for a known familial variant Adult child of Marfan proband; adolescent sibling of HCM proband (with assent/consent nuance)

Carrier testing Detect heterozygotes for AR/XL reproductive risk SMA SMN1 dosage with residual-risk counseling; Tay-Sachs enzyme/DNA; Fragile X for reproductive planning

Hard rule: Do not counsel a newborn-screen positive as a final diagnosis. Say “screen positive—confirmatory metabolic/molecular testing is required,” then discuss interim safety measures (e.g., feeding changes, fasting avoidance) as directed by the metabolic team.

  • Surveillance Matrices You Should Be Able to Rebuild
  • Metabolic / Storage

Condition Surveillance / sick-day focus Treatment lever

PKU Phe levels, nutrition, neurodevelopment; preconception control for women Diet ± BH4-responsive therapy / pegvaliase pathways

Galactosemia Diet adherence, development, speech, ovarian function in females Lactose/galactose restriction

Urea-cycle (OTC etc.) Illness protocols, ammonia access plan, liver-transplant discussions in severe disease Protein management, scavengers, dialysis acutely

  • Gaucher type 1 Blood counts, visceral/bone assessments ERT / SRT
  • Pompe Motor/respiratory/cardiac metrics ERT; early Rx critical in infantile form
  • MCADD Growth, avoidance of fasting, emergency letter currency Prevent crises with nutrition/glucose support
  • Neuromuscular / Fragile X

Condition Surveillance focus Treatment / support lever

DMD/BMD (+ carriers) Steroid/era-specific motor care, respiratory, cardiac ; carrier echo Multidisciplinary supportive care; evolving molecular therapies—counsel as time-sensitive referrals

  • DM1 ECG/arrhythmia, weakness, cataracts, endocrine Supportive; family cascade for conduction disease
  • SMA Respiratory/motor milestones; therapy response Disease-modifying therapies; earlier better
  • FXS Development, behavior, educational supports Supportive therapies; cascade FMR1 testing
  • FXTAS / FXPOI Neuro / reproductive endocrine follow-up Symptom management; fertility planning
  • Connective Tissue / Cardiovascular
  • Condition Surveillance focus Treatment lever
  • Marfan / LDS Serial aortic/arterial imaging; ophthalmology (Marfan) Meds, activity limits, surgical thresholds

vEDS BP control, emergency vascular plan, pregnancy planning Avoidance of high-risk elective procedures without expertise

  • HCM Echo/ECG, risk stratification for SCD Meds, septal reduction selected, ICD selected
  • ARVC Arrhythmia surveillance; exercise counseling Meds/ICD; activity modification
  • LQTS QTc, trigger avoidance, drug lists β-blockers; ICD selected
  • Diagnostic Strategy: Choosing the Right Test Tier

Clinical suspicion First-tier thinking

Suspected chromosomal/syndromic DD with malformations Chromosomal microarray (± karyotype if balanced rearrangement/aneuploidy strongly suspected)

  • Classic single-gene phenotype with clear target (DMD, FBN1, FMR1 CGG) Targeted gene/repeat assay first
  • Overlapping aortopathy (Marfan vs LDS vs vEDS) Multigene aortopathy panel
  • Broad cardiomyopathy/arrhythmia differential Condition-specific cardiac gene panel
  • Infantile metabolic crisis Concurrent biochemical critical labs + targeted/gene panel per metabolic genetics

Nonspecific hypotonia/DD after CMA Consider neuromuscular/metabolic panels or exome with phenotypes captured precisely

Known familial variant Site-specific testing for relatives (cheaper, clearer)

Urgency modifier: In neonatal hyperammonemia or infantile Pompe with respiratory failure, stabilize and treat empirically while confirmatory genetics are pending. Test selection must not delay rescue.

Treatment Themes as Exam Shortcuts

  • Lever class Conditions
  • Substrate/diet control PKU, galactosemia, urea-cycle protein management, MCADD fasting avoidance
  • Enzyme / substrate reduction Gaucher, Pompe (ERT); selected others
  • Gene dosage / splicing / gene therapy era SMA (and evolving DMD molecular therapies—know to refer early)
  • Mechanical catastrophe prevention Aortic surgery thresholds; ICD; β-blockers in LQTS/aortopathy

Reproductive risk tools PGT/prenatal diagnosis after familial variant known; maternal PKU diet; FXPOI fertility planning

Putting It Together: Four Exam-Style Scripts

Screen-positive NBS for MCADD: Interim no-prolonged-fasting plan → confirmatory acylcarnitine/gene testing → parental counseling for AR recurrence → sibling evaluation → emergency letter.

Mother of boy with DMD: Offer carrier testing → if positive, cardiac surveillance + reproductive options → discuss germline mosaicism if leukocyte negative → cascade maternal female relatives.

Proband with LDS gene variant: Arterial imaging plan → cascade first-degree relatives → pregnancy/activity counseling → distinguish from Marfan management nuances.

Woman with FMR1 premutation seeking fertility advice: FXPOI risk → reproductive timeline/endocrine referral → expansion risk education → offer testing to relatives of reproductive age.

Common Framework Traps

Trap Correction

Treating carrier screening as diagnostic testing Carriers are usually healthy; risk is reproductive (except XL manifesting carriers, FXPOI/FXTAS, DMD cardiac risk)

Skipping cascade after a clear AD aortopathy/cardiomyopathy result Relatives share up to 50% risk—silence is harmful

  • Assuming all EDS needs the same surveillance vEDS ≠ hypermobile EDS
  • Quoting SMN1 carrier negative as zero risk Explain [2+0] residual risk
  • Delaying metabolic rescue for perfect genotyping Treat ammonia/hypoglycemia first

Mastering this framework lets you answer Domain 1C items even when the rare disease name is unfamiliar: identify the catastrophe, pick the correct test role, cascade, surveil, and treat.